CTT Expands Management Team Appointing Lucie Letellier to Chief Financial Officer

Toronto, Ontario / TNW-ACCESSWIRE / November 6th, 2014 / The Board of Directors of Mindesta Inc. (OTCBB: MDST) is pleased to announce the appointment of Lucie Lettellier to Chief Financial Officer (CFO) of CTT Pharmaceuticals, effective immediately.

Lucie Letellier is a financial professional with specialization in finance and accounting. From 2005 to 2009 Lucie was the CFO of Paramount Gold and Silver Corp. (NYSE/TSX: PZG) having contributed to the development of the company from a private enterprise through private capital raising and 2 public listings overseeing $30 million in equity financing. Ms. Letellier has 25 years experience as a senior accountant in the office of a Chartered Professional Accountant. Her skills include financial reporting, tax compliance, corporate governance and continuous disclosure requirements. Her work experience also includes credit, loan officer and controller for private enterprises

"We are extremely pleased to have Ms. Lucie Letellier join our management team as CFO. Her depth and experience in the public markets will aid the company in executing its vision. " stated Dr. Pankaj Modi.


ABOUT CTT PHARMACEUTICALS:

CTT Pharma has invented and developed an ideal intra-oral, sublingual, fast-dissolving wafer drug delivery system, complete with a mobile backend tracking software designed to increase patient compliance and prevent physical addiction.

CTT Pharma's principal asset is a patented, orally administered, fast dissolving wafer (the "Wafer")

The Wafer formulation is protected by Canadian Patent Number CA 2624110 C and US Patent Number 8,823,401 B2. The Canadian Patent, is a blanket patent covering most pharmaceutical agents (an open patent) and US Patent consist of approved opiates; such as Fentanyl, Morphine, Codeine etc.

CTT Pharma's primary mission is to lower addiction and improve overall compliance within the pain management market, specifically opiates, through the use of improved drug delivery and novel IT technology. This technology platform will be targeting both the human and pet (Veterinarian) markets.

CTT Pharma's Oral fast dissolving drug delivery systems will consist of films and wafers that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system, mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficiency of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing.

Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its technology will be the first to gain widespread use in major markets such as Pain Management (MedWafe), Veterinary Medicine(VetWafe) as well as Medicinal Marijuana(Cannawafe).



For additional information, please contact:

Dean Hanisch, President
CTT Pharmaceuticals
Tel: 613 612-6060
Website: www.cttpharmaceuticals.com



Forward Looking Statements:

This press release contains forward-looking statements, which can be identified by the use of statements that include words such as "could", "potential", "believe", "expect", "anticipate", "intend", "plan", "likely", "will" or other similar words or phrases. These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. The Company does not intend, and does not assume any obligation, to update forward-looking statements, whether as a result of new information, future events or otherwise, unless otherwise required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.

NO REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THE CONTENTS OF THIS RELEASE